Cargando…
The Therapeutic Strategies for SLE by Targeting Anti-dsDNA Antibodies
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by diverse serological autoantibodies. Anti-dsDNA antibodies are involved in multiple organ damage, especially the kidney, skin, and central nervous system. Anti-dsDNA antibodies play a pivotal role in SLE, and research...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464114/ https://www.ncbi.nlm.nih.gov/pubmed/34542806 http://dx.doi.org/10.1007/s12016-021-08898-7 |
_version_ | 1784787511481991168 |
---|---|
author | Wang, Yaqi Xiao, Shengxiang Xia, Yumin Wang, Huixia |
author_facet | Wang, Yaqi Xiao, Shengxiang Xia, Yumin Wang, Huixia |
author_sort | Wang, Yaqi |
collection | PubMed |
description | Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by diverse serological autoantibodies. Anti-dsDNA antibodies are involved in multiple organ damage, especially the kidney, skin, and central nervous system. Anti-dsDNA antibodies play a pivotal role in SLE, and researchers have developed therapeutic strategies targeting these antibodies. Approaches to reduce anti-dsDNA antibodies via B cell targeted biologics against B cell surface antigens, B cell survival factors, or Bruton’s tyrosine kinase have effectively eliminated B cells. However, their non-specific depletion hampers normal immune system functioning and limits the therapeutic benefits. Thus, scientists have attempted anti-dsDNA antibodies or lupus-specific strategies, such as the immature dendritic cell vaccine and immunoadsorption. Recently, synthetic mimic peptides (hCDR1, pCONs, DWEYS, FISLE-412, and ALW) that directly block anti-dsDNA autoantibodies have attracted attention, which could ameliorate lupus, decrease the serological autoantibody titer, reduce the deposition of renal autoantibodies, and improve pathological performance. These potent small peptide molecules are well tolerated, non-toxic, and non-immunogenic, which have demonstrated a benign safety profile and are expected to be hopeful candidates for SLE management. In this review, we clarify the role of anti-dsDNA antibodies in SLE, mainly focus on the current strategies targeting anti-dsDNA antibodies, and discuss their potential clinical value. |
format | Online Article Text |
id | pubmed-9464114 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-94641142022-09-12 The Therapeutic Strategies for SLE by Targeting Anti-dsDNA Antibodies Wang, Yaqi Xiao, Shengxiang Xia, Yumin Wang, Huixia Clin Rev Allergy Immunol Article Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by diverse serological autoantibodies. Anti-dsDNA antibodies are involved in multiple organ damage, especially the kidney, skin, and central nervous system. Anti-dsDNA antibodies play a pivotal role in SLE, and researchers have developed therapeutic strategies targeting these antibodies. Approaches to reduce anti-dsDNA antibodies via B cell targeted biologics against B cell surface antigens, B cell survival factors, or Bruton’s tyrosine kinase have effectively eliminated B cells. However, their non-specific depletion hampers normal immune system functioning and limits the therapeutic benefits. Thus, scientists have attempted anti-dsDNA antibodies or lupus-specific strategies, such as the immature dendritic cell vaccine and immunoadsorption. Recently, synthetic mimic peptides (hCDR1, pCONs, DWEYS, FISLE-412, and ALW) that directly block anti-dsDNA autoantibodies have attracted attention, which could ameliorate lupus, decrease the serological autoantibody titer, reduce the deposition of renal autoantibodies, and improve pathological performance. These potent small peptide molecules are well tolerated, non-toxic, and non-immunogenic, which have demonstrated a benign safety profile and are expected to be hopeful candidates for SLE management. In this review, we clarify the role of anti-dsDNA antibodies in SLE, mainly focus on the current strategies targeting anti-dsDNA antibodies, and discuss their potential clinical value. Springer US 2021-09-20 2022 /pmc/articles/PMC9464114/ /pubmed/34542806 http://dx.doi.org/10.1007/s12016-021-08898-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Wang, Yaqi Xiao, Shengxiang Xia, Yumin Wang, Huixia The Therapeutic Strategies for SLE by Targeting Anti-dsDNA Antibodies |
title | The Therapeutic Strategies for SLE by Targeting Anti-dsDNA Antibodies |
title_full | The Therapeutic Strategies for SLE by Targeting Anti-dsDNA Antibodies |
title_fullStr | The Therapeutic Strategies for SLE by Targeting Anti-dsDNA Antibodies |
title_full_unstemmed | The Therapeutic Strategies for SLE by Targeting Anti-dsDNA Antibodies |
title_short | The Therapeutic Strategies for SLE by Targeting Anti-dsDNA Antibodies |
title_sort | therapeutic strategies for sle by targeting anti-dsdna antibodies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464114/ https://www.ncbi.nlm.nih.gov/pubmed/34542806 http://dx.doi.org/10.1007/s12016-021-08898-7 |
work_keys_str_mv | AT wangyaqi thetherapeuticstrategiesforslebytargetingantidsdnaantibodies AT xiaoshengxiang thetherapeuticstrategiesforslebytargetingantidsdnaantibodies AT xiayumin thetherapeuticstrategiesforslebytargetingantidsdnaantibodies AT wanghuixia thetherapeuticstrategiesforslebytargetingantidsdnaantibodies AT wangyaqi therapeuticstrategiesforslebytargetingantidsdnaantibodies AT xiaoshengxiang therapeuticstrategiesforslebytargetingantidsdnaantibodies AT xiayumin therapeuticstrategiesforslebytargetingantidsdnaantibodies AT wanghuixia therapeuticstrategiesforslebytargetingantidsdnaantibodies |